Sarcoidosis treatment and outcomes: what is most important to patients?

J. Boyd (London, United Kingdom), R. Baughman (Cincinnati, United States of America), D. Valeyere (Paris, France), A. Álvarez Rodríguez (Santander, Spain), L. Charvoz (Lausanne, Switzerland), H. Faber (Meerbusch , Germany), C. Knoet (The Hague, Netherlands), F. Martone (Bologna, Italy), D. Novel (Yverdon-les-Bains, Switzerland), B. Quadder (Meerbusch, Germany), J. Richardson (London, United Kingdom), G. Spitzer (Chicago, United States of America), G. Ziosi (Bologna, Italy), J. Hochreiter (Neulengbach, Austria)

Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Session: Sarcoidosis: from basic research to patient outcomes
Session type: Poster Discussion
Number: 5219
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Boyd (London, United Kingdom), R. Baughman (Cincinnati, United States of America), D. Valeyere (Paris, France), A. Álvarez Rodríguez (Santander, Spain), L. Charvoz (Lausanne, Switzerland), H. Faber (Meerbusch , Germany), C. Knoet (The Hague, Netherlands), F. Martone (Bologna, Italy), D. Novel (Yverdon-les-Bains, Switzerland), B. Quadder (Meerbusch, Germany), J. Richardson (London, United Kingdom), G. Spitzer (Chicago, United States of America), G. Ziosi (Bologna, Italy), J. Hochreiter (Neulengbach, Austria). Sarcoidosis treatment and outcomes: what is most important to patients?. 5219

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: